Plant Name: Arnebia euchroma
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| GAA; | |
| TDP1; RECQL; PKM; IDO1; AKR1B1; ALDH1A1; SOAT1; APEX1; POLB; | |
| CDC25B; | |
| MAPK1; MAP2K1; | |
| CA12; CA7; CA4; | |
| PPARA; PPARD; | |
| MAOA; MAOB; | |
| MMP1; | |
| TLR2; | |
| TP53; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; MCL1; MAPT; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | SOAT1 | Acyl coenzyme A:cholesterol acyltransferase 1 | P35610 | CHEMBL2782 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.112E-07 | 4.842E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.443E-06 | 2.418E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.849E-06 | 2.585E-03 | AKR1B1, ALDH1A1, APEX1, CYP3A4, GAA, IDO1, MAOA, MAOB, PKM, PPARD |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.190E-06 | 2.778E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 3.629E-06 | 3.040E-03 | AKR1B1, ALDH1A1, CYP3A4, IDO1, MAOA, MAOB, PKM, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 6.424E-06 | 4.321E-03 | LMNA, PKM, PPARA, PPARD, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 6.525E-06 | 4.321E-03 | AKR1B1, APEX1, MAOB, MAPK1, POLB, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 7.826E-06 | 4.733E-03 | AKR1B1, ALDH1A1, GAA, PKM, PPARD |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 9.236E-06 | 5.111E-03 | AKR1B1, ALDH1A1, CYP3A4, PPARD, SOAT1, TTR |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 1.227E-05 | 6.215E-03 | AKR1B1, FABP5, GAA, LMNA, MAOB, MAP2K1, MAPK1, MCL1, PKM, POLB, PPARA, PPARD, SMN1, SMN2, TLR2, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 1.909E-05 | 8.498E-03 | MAP2K1, MAPK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.650E-11 | 4.081E-09 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARA; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.599E-07 | 5.851E-05 | MAP2K1; MMP1; MAPK1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.289E-06 | 1.651E-04 | MAP2K1; LMNA; MAPK1; TP53; MCL1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.569E-06 | 1.715E-04 | MAP2K1; PKM; MAPK1; TP53 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.268E-05 | 8.932E-04 | MAP2K1; MAOB; MAOA; MAPK1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 7.693E-05 | 1.316E-03 | MAP2K1; MAPK1; MAPT; TP53; CDC25B |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.739E-05 | 4.463E-04 | MAP2K1; MAPK1; TP53 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.283E-06 | 1.651E-04 | CA12; CA4; CA7 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.640E-05 | 8.932E-04 | MAOB; MAOA; IDO1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.197E-04 | 1.595E-03 | MAP2K1; MAPK1; TP53; TLR2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.023E-04 | 1.575E-03 | MAP2K1; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.277E-04 | 1.595E-03 | MAP2K1; MAPK1; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.573E-04 | 1.730E-03 | MAP2K1; MAPK1; TP53; CDC25B; MCL1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.346E-04 | 1.595E-03 | MAP2K1; MAPK1; PPARD |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.991E-04 | 1.887E-03 | MAP2K1; MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.730E-04 | 1.776E-03 | MAP2K1; MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.983E-04 | 2.088E-03 | MAP2K1; MAPK1; TP53; TLR2; MCL1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.083E-04 | 1.887E-03 | MAP2K1; MAPK1; TP53 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 2.615E-04 | 2.014E-03 | MAP2K1; MAOB; MAOA; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.586E-04 | 2.014E-03 | MAP2K1; MAPK1; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.216E-04 | 2.592E-03 | MAP2K1; MAPK1; TP53; TLR2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.911E-04 | 2.554E-03 | MAP2K1; MAPK1; PPARA; TSHR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.377E-04 | 2.014E-03 | MAOB; MAOA; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.808E-04 | 2.059E-03 | MAP2K1; MAPK1; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.376E-04 | 2.592E-03 | POLB; PKM; MAPK1; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.973E-04 | 3.285E-03 | MAP2K1; MMP1; MAPK1; TP53; PPARD |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.029E-04 | 2.869E-03 | MAP2K1; MAPK1; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.664E-04 | 3.539E-03 | MAP2K1; MAPK1; CDC25B |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.110E-03 | 5.127E-03 | PKM; MAOB; MAOA; GAA; ALDH1A1; AKR1B1; CYP3A4; IDO1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.372E-04 | 4.159E-03 | MAP2K1; MAPK1; TLR2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.142E-03 | 5.127E-03 | MAP2K1; MAPK1; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.198E-03 | 5.127E-03 | MAP2K1; MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.198E-03 | 5.127E-03 | MAP2K1; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.611E-03 | 6.359E-03 | MAPK1; PPARA; TP53 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.103E-03 | 1.637E-02 | MAP2K1; MAPK1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.014E-02 | 2.740E-02 | MAP2K1; MAPK1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 6.304E-03 | 1.832E-02 | MAP2K1; MAPK1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.318E-03 | 1.446E-02 | FABP4; TSHR |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 4.941E-03 | 1.619E-02 | MAP2K1; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.105E-02 | 2.836E-02 | MAP2K1; MAPK1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.042E-03 | 1.989E-02 | MAP2K1; MAPK1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.298E-02 | 3.194E-02 | MAP2K1; MAPK1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.233E-03 | 1.989E-02 | MAP2K1; MAPK1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.949E-03 | 1.796E-02 | MAP2K1; MAPK1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.323E-02 | 3.194E-02 | MAP2K1; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.152E-02 | 2.908E-02 | MAP2K1; MAPK1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 6.125E-03 | 1.814E-02 | MAOB; MAOA |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.348E-02 | 3.194E-02 | PKM; PPARA |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 5.949E-03 | 1.796E-02 | MAP2K1; MAPK1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.348E-02 | 3.194E-02 | MAP2K1; MAPK1 |
| hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 1.082E-02 | 2.824E-02 | MMP1; TLR2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.036E-02 | 2.752E-02 | MAP2K1; MAPK1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.775E-03 | 1.796E-02 | ALDH1A1; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.399E-02 | 3.227E-02 | MAP2K1; MAPK1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.612E-02 | 3.546E-02 | MAP2K1; MAPK1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.585E-02 | 3.537E-02 | MAP2K1; MAPK1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.233E-03 | 1.989E-02 | MAPK1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.425E-02 | 3.227E-02 | MAPK1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.425E-02 | 3.227E-02 | MAP2K1; MAPK1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.809E-02 | 3.924E-02 | MAPK1; TLR2 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.955E-02 | 4.125E-02 | MAP2K1; MAPK1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 3.191E-03 | 1.143E-02 | PKM; MAPK1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.867E-02 | 3.993E-02 | MAP2K1; MAPK1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.231E-02 | 4.522E-02 | MAP2K1; MAPK1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.138E-02 | 4.390E-02 | MAOB; MAOA |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.263E-02 | 4.526E-02 | MAP2K1; MAPK1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.359E-02 | 4.599E-02 | TP53; TLR2 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.327E-02 | 4.594E-02 | MAP2K1; MAPK1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.985E-02 | 4.132E-02 | TP53; CDC25B |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.556E-02 | 4.800E-02 | TP53; PPARD |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 3.323E-03 | 1.163E-02 | MAOB; MAOA |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.457E-02 | 4.729E-02 | MAP2K1; MAPK1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 3.457E-03 | 1.183E-02 | MAOB; MAOA |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.556E-02 | 4.800E-02 | MAP2K1; MAPK1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.623E-02 | 4.867E-02 | MAP2K1; MAPK1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.016E-03 | 4.889E-03 | MAP2K1; MAPK1 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.707E-03 | 6.412E-03 | MAP2K1; MAPK1 |
| hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 2.226E-03 | 8.161E-03 | MAOB; MAOA |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.255E-03 | 5.223E-03 | GAA; AKR1B1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.707E-03 | 6.412E-03 | MAOB; MAOA |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.518E-03 | 6.153E-03 | POLB; APEX1 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 8.015E-04 | 4.114E-03 | MAOB; MAOA |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 3.980E-04 | 2.554E-03 | MAOB; MAOA |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAOB; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAOB; MAPT |
| NA: NA | Motor symptoms | NA | MAOB |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAOB; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; MAOB |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; IDO1; MAPK1; TLR2; MCL1; CDC25B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; MAOB |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; MAPK1; TLR2; PKM |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; AKR1B1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; MAOB |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAOB; MAPT |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; MAOA; MAOB |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; MAOB; MAOB |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |